Literature DB >> 18453748

Expression of the counter-regulatory peptide intermedin is augmented in the presence of oxidative stress in hypertrophied cardiomyocytes.

David Bell1, Youyou Zhao, Francis P G McCoy, Adrian Devine, Barbara J McDermott.   

Abstract

BACKGROUND: Intermedin (IMD), a novel cardiac peptide related to adrenomedullin (AM), protects against myocardial ischemia-reperfusion injury and attenuates ventricular remodelling. IMD's actions are mediated by a calcitonin receptor-like receptor in association with receptor activity modifying proteins (RAMPs 1-3). AIM/
METHOD: using the spontaneously hypertensive rat (SHR) and normotensive Wistar Kyoto (WKY) rat at 20 weeks of age, to examine (i) the presence of myocardial oxidative stress and concentric hypertrophy; (ii) expression of IMD, AM and receptor components.
RESULTS: In left and right ventricular cardiomyocytes from SHR vs. WKY cell width (26% left, 15% right) and mRNA expression of hypertrophic markers ANP (2.7 fold left, 2.7 fold right) and BNP (2.2 fold left, 2.0 fold right) were enhanced. In left ventricular cardiomyocytes only (i) oxidative stress was indicated by increased membrane protein carbonyl content (71%) and augmented production of O(2-) anion (64%); (ii) IMD (6.8 fold), RAMP1 (2.5 fold) and RAMP3 (2.0 fold) mRNA was increased while AM and RAMP2 mRNA was not altered; (iii) abundance of RAMP1 (by 48%), RAMP2 (by 41%) and RAMP3 (by 90%) monomers in cell membranes was decreased.
CONCLUSION: robust augmentation of IMD expression in hypertrophied left ventricular cardiomyocytes indicates a prominent role for this counter-regulatory peptide in the adaptation of the SHR myocardium to the stresses imposed by chronic hypertension. The local concentration and action of IMD may be further enhanced by down-regulation of NEP within the left ventricle. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18453748     DOI: 10.1159/000129633

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  8 in total

Review 1.  Adrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases.

Authors:  Song-Yang Zhang; Ming-Jiang Xu; Xian Wang
Journal:  Br J Pharmacol       Date:  2017-05-16       Impact factor: 8.739

2.  Rat intermedin1-47 does not improve functional recovery in postischemic hearts.

Authors:  Gerald Münzel; Alexander Schlier; Rolf Schreckenberg; Yaser Abdallah; Klaus-Dieter Schlüter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-01       Impact factor: 3.000

3.  AM₁-receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury.

Authors:  David Bell; Malcolm Campbell; Matthew Ferguson; Leah Sayers; Liz Donaghy; Anna O'Regan; Victoria Jewhurst; Mark Harbinson
Journal:  J Physiol       Date:  2011-12-19       Impact factor: 5.182

4.  Reverse myocardial effects of intermedin in pressure-overloaded hearts: role of endothelial nitric oxide synthase activity.

Authors:  Ana Luísa Pires; Marta Pinho; Bárbara Silvana Alves; Sónia Pinho; Cristina Sena; Raquel Maria Seica; Adelino F Leite-Moreira
Journal:  J Physiol       Date:  2012-11-19       Impact factor: 5.182

5.  Inhibition of endoplasmic reticulum stress by intermedin(1-53) protects against myocardial injury through a PI3 kinase-Akt signaling pathway.

Authors:  Xu Teng; Junqiu Song; Gaigai Zhang; Yan Cai; Fang Yuan; Jie Du; Chaoshu Tang; Yongfen Qi
Journal:  J Mol Med (Berl)       Date:  2011-09-11       Impact factor: 4.599

6.  Intermedin protects against myocardial ischemia-reperfusion injury in diabetic rats.

Authors:  Hong Li; Yunfei Bian; Nana Zhang; Jia Guo; Cheng Wang; Wayne Bond Lau; Chuanshi Xiao
Journal:  Cardiovasc Diabetol       Date:  2013-06-18       Impact factor: 9.951

7.  Intermedin in the paraventricular nucleus attenuates cardiac sympathetic afferent reflex in chronic heart failure rats.

Authors:  Xian-Bing Gan; Hai-Jian Sun; Dan Chen; Ling-Li Zhang; Hong Zhou; Li-Yan Chen; Ye-Bo Zhou
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

8.  Implication of plasma intermedin levels in patients who underwent first-time diagnostic coronary angiography: a single centre, cross-sectional study.

Authors:  Aylin Hatice Yamac; Ahmet Bacaksiz; Ziya Ismailoglu; Sitki Kucukbuzcu; Emrah Sevgili; Emin Asoglu; Muharrem Nasifov; Parviz Jafarov; Ercan Erdogan; Omer Goktekin
Journal:  BMC Cardiovasc Disord       Date:  2014-12-11       Impact factor: 2.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.